新型选择性RET抑制剂BYS10在临床前模型中表现出强大的抗瘤活性
Fei Qin1, Yiman Chen1, Jinhai Deng1
1Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd., Baiyunshan Pharmaceutical General Factory/Guangdong Province Key Laboratory for Core Technology of Chemical Raw Materials and Pharmaceutical Formulations, Guangzhou, China.
Frontiers in pharmacology
|November 3, 2025
概括
BYS10是一种新型RET抑制剂,对各种RET变化表现出强大的活性,在临床前模型中表现优于Selpercatinib. 它的研究新药批准突出了其治疗RET驱动癌症的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 异常的RET基因变异导致多种癌症.
- 抑制RET激酶是一种关键的治疗策略.
- 获得的耐药性限制了当前RET抑制剂的疗效.
研究的目的:
- 评估BYS10作为一种新型RET抑制剂.
- 评估BYS10对野生类型RET和耐药突变的疗效.
- 为了比较BYS10的抗瘤活性与Selpercatinib.
主要方法:
- 酶分析测试以确定IC50值.
- 在体外细胞增殖抑制试验.
- 在体内异种移植模型评估抗瘤功效.
- 西方斑点和分子对接用于机制验证.
主要成果:
- BYS10对野生类型的RET和6种RET突变/融合表现出较低的纳米分子效力.
- 在RET改变的细胞系中观察到显著的抗增殖活性.
- 与Selpercatinib相比,BYS10在临床前异种移植模型中显示出更高的抗瘤疗效.
- BYS10证实了强大的RET酸化抑制和优化的结合RET G810R/S.
结论:
- BYS10是一种高度选择性的RET抑制剂,具有卓越的体外和体内活性.
- BYS10显示了RET驱动的恶性瘤的显著治疗潜力.
- 美国FDA和NMPA的研究新药批准支持BYS10的临床开发.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K


